参考文献/References:
［1］ Smithwick RH. Hypertensive vascular disease; results of and indications for splanchnicectomy［J］. J Chronic Dis, 1955, 1: 477- 496.
［2］ Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases［J］. Lancet, 1953, 1: 403- 408.
［3］ Krum H, Schlaich M, Whitbourn R, et al. Catheter- based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof- of- principle cohort study［J］. Lancet, 2009, 373: 1275- 1281.
［4］ Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study［J］. Circulation, 2011, 123: 1940- 1946.
［5］ Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension［J］. J Am Coll Cardiol, 2012, 60: 1163- 1170.
［6］ Sobotka PA, Mahfoud F, Schlaich MP, et al. Sympatho- renal axis in chronic disease［J］. Clin Res Cardiol, 2011, 100: 1049- 1057.
［7］ Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea［J］. Hypertension, 2011, 58: 559- 565.
［8］ Bhatt DL, Kandzari DE, O’neill WW, et al. A controlled trial of renal denervation for resistant hypertension［J］. N Engl J Med, 2014, 370: 1393- 1401.
［9］ Bertog SC, Sobotka PA, Sievert H. Renal denervation for hypertension［J］. JACC Cardiovasc Interv, 2012, 5: 249- 258.
［10］ Atherton DS, Deep NL, Mendelsohn FO. Micro- anatomy of the renal sympathetic nervous system: a human postmortem histologic study［J］. Clin Anat, 2012, 25: 628- 633.
［11］ 朱清一， 彭 文， 柴湘平， 等． 肾交感神经导管消融术治疗难治性高血压临床研究进展［J］． 介入放射学杂志， 2012， 21： 692- 695．
［12］ Kirchheim H, Ehmke H, Persson P. Sympathetic modulation of renal hemodynamics, renin release and Sodium excretion［J］. Klin Wochenschr, 1989, 67: 858- 864.
［13］ Bell- Reuss E, Trevino DL, Gottschalk CW. Effect of renal sympat- hetic nerve stimulation on proximal water and Sodium reabsorption［J］. J Clin Invest, 1976, 57: 1104- 1107.
［14］ Dibona GF. Nervous kidney. Interaction between renal sympathetic nerves and the renin- angiotensin system in the control of renal function［J］. Hypertension, 2000, 36: 1083- 1088.
［15］ Liu L, Barajas L. The rat renal nerves during development［J］. Anat Embryol （Berl）, 1993, 188: 345- 361.
［16］ Morsing P, Persson AE. Pelvic pressure and tubuloglomerular feedback in hydronephrosis［J］. Ren Physiol Biochem, 1990, 13: 181- 189.
［17］ 杨 宁， 程康安， 李拥军． 去肾交感神经支配术与高血压［J］．介入放射学杂志， 2012， 21： 441- 446．
［18］ DiBona GF, Kopp UC. Neural control of renal function［J］. Physiol Rev, 1997, 77: 75- 197.
［19］ 周 耕， 卢 川， 程永德． 肾交感神经消融术临床研究进展［J］． 介入放射学杂志， 2013， 22： 1- 7．
［20］ Penesova A, Radikova Z, Cizmarova E, et al. The role of norepinephrine and insulin resistance in an early stage of hypertension［J］. Ann N Y Acad Sci, 2008, 1148: 490- 494.
［21］ Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension［J］. Circulation, 2003, 108: 3097- 3101.
［22］ Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model［J］. J Am Coll Cardiol, 2009, 54: 375- 385.
［23］ Grassi G, Facchini A, Trevano FQ, et al. Obstructive sleep apnea- dependent and- independent adrenergic activation in obesity［J］. Hypertension, 2005, 46: 321- 325.
［24］ 吕天石， 邹英华． 经导管肾动脉交感神经射频消融术治疗顽固性高血压研究进展［J］． 中华介入放射学电子杂志， 2013： 65- 66．
［25］ Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research［J］. Circulation,2008, 117: e510- e526.
［26］ Symplicity HTN- 1 Investigators. Catheter- based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months［J］. Hypertension, 2011, 57: 911- 917.
［27］ Krum H, Schlaich MP, Bohm M, et al. Percutaneous renal denervation in patients with treatment- resistant hypertension: final 3- year report of the Symplicity HTN- 1 study［J］. Lancet, 2014, 383: 622- 629.
［28］ Symplicity HTN- 2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment- resistant hypertension（The Symplicity HTN- 2 Trial）: a randomised controlled trial［J］. Lancet, 2010, 376: 1903- 1909.
［29］ Esler MD, Krum H, Schlaich M, et al. Renal sympathetic denervation for treatment of drug- resistant hypertension: one- year results from the Symplicity HTN- 2 randomized, controlled trial［J］. Circulation, 2012, 126: 2976- 2982.
［30］ Esler MD, Bohm M, Sievert H, et al. Catheter- based renal denervation for treatment of patients with treatment- resistant hypertension: 36 month results from the SYMPLICITY HTN- 2 randomized clinical trial［J］. Eur Heart J, 2014, 35: 1752- 1759.
［31］ Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter- based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN- 3 Trial［J］. Clin Cardiol, 2012, 35: 528- 535.
［32］ Rodriguez- Leor O, Bonet J, Bayes- Genis A. Renal denervation for resistant hypertension［J］. N Engl J Med, 2014, 371: 182- 183.
［33］ 蒋雄京， 董 徽． SYMPLICITY HTN- 3结果阴性不能否定经导管肾神经消融理念［J］． 中国循环杂志， 2014： 404- 405．
［34］ Luscher TF, Mahfoud F. Renal nerve ablation after SYMPLICITY HTN- 3: confused at the higher level?［J］. Eur Heart J, 2014, 35: 1706- 1711.
［35］ Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension （DENERHTN）: a multicentre, open- label, randomised controlled trial［J］. Lancet, 2015, 385: 1957- 1965.
［36］ Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome［J］. J Hypertens, 2007, 25: 909- 920.
［37］ Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome?［J］. J Hypertens, 2011, 29: 991- 996.
［38］ Verloop WL, Spiering W, Vink EE, et al. Denervation of the renal arteries in metabolic syndrome: the DREAMS- study［J］. Hypertension, 2015, 65: 751- 757.
［39］ Brinkmann J, Heusser K, Schmidt BM, et al. Catheter- based renal nerve ablation and centrally generated sympathetic activity in difficult- to- control hypertensive patients: prospective case series［J］. Hypertension, 2012, 60: 1485- 1490.
［40］ Hering D, Lambert EA, Marusic P, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension［J］. Hypertension, 2013, 61: 457- 464.
［41］ Arimoto T, Tada H, Igarashi M, et al. High washout rate of iodine- 123- metaiodobenzylguanidine imaging predicts the outcome of catheter ablation of atrial fibrillation［J］. J Cardiovasc Electrophysiol, 2011, 22: 1297- 1304.
［42］ Pokushalov E, Romanov A, Katritsis DG, et al. Renal denervation for improving outcomes of catheter ablation in patients with atrial fibrillation and hypertension: early experience［J］. Heart Rhythm, 2014, 11: 1131- 1138.
［43］ Ukena C, Mahfoud F, Kindermann I, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension［J］. J Am Coll Cardiol, 2011, 58: 1176- 1182.
［44］ Ukena C, Mahfoud F, Spies A, et al. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension［J］. Int J Cardiol, 2013, 167: 2846- 2851.
［45］ Ukena C, Bauer A, Mahfoud F, et al. Renal sympathetic denervation for treatment of electrical storm: first- in- man experience［J］. Clin Res Cardiol, 2012, 101: 63- 67.
［46］ Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension［J］. J Am Coll Cardiol, 2012, 59: 901- 909.
［47］ Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic- nerve ablation for uncontrolled hypertension［J］. N Engl J Med, 2009, 361: 932- 934.
［48］ Lansdown A, Rees DA. The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target?［J］. Clin Endocrinol （Oxf）, 2012, 77: 791- 801.
［49］ Hausberg M, Grassi G. Mechanisms of sympathetic overactivity in patients with chronic renal failure: a role for chemoreflex activation?［J］. J Hypertens, 2007, 25: 47- 49.
［50］ 代子玄， 赵庆彦． 经导管介入肾去交感神经的基础和临床研究进展［J］． 中华心律失常学杂志， 2013， 17： 386- 389．
［51］ Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter- based renal sympathetic denervation in patients with resistant hypertension［J］. Hypertension, 2012, 60: 419- 424.
［52］ Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD［J］. J Am Soc Nephrol, 2012, 23: 1250- 1257.
［53］ Davies JE, Manisty CH, Petraco R, et al. First- in- man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH- Pilot study［J］. Int J Cardiol, 2013, 162: 189- 192.